Summit X LLC Buys 75 Shares of Johnson & Johnson (NYSE:JNJ)

Summit X LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,776 shares of the company’s stock after acquiring an additional 75 shares during the quarter. Summit X LLC’s holdings in Johnson & Johnson were worth $626,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Atlantic Private Wealth LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $32,000. 25 LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $55,000. Horizons Wealth Management grew its position in Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares during the period. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $66,000. Finally, Mcmillion Capital Management Inc. purchased a new position in Johnson & Johnson during the 2nd quarter worth $103,000. Institutional investors own 68.40% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. Barclays lifted their price objective on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. Atlantic Securities lifted their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Friday. Morgan Stanley cut their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 18th. Finally, Raymond James cut their price target on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Johnson & Johnson Trading Down 0.2 %

Shares of Johnson & Johnson stock opened at $149.79 on Monday. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $181.04. The stock’s 50-day simple moving average is $154.77 and its 200 day simple moving average is $160.38. The stock has a market capitalization of $360.59 billion, a P/E ratio of 11.12, a P/E/G ratio of 3.00 and a beta of 0.58. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. The firm had revenue of $21.35 billion for the quarter, compared to analysts’ expectations of $21 billion. As a group, research analysts anticipate that Johnson & Johnson will post 10.1 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s dividend payout ratio is presently 35.34%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.